OCULAR THERAPEUTIX INC

For the period ended Dec 31, 2023. Filed Mar 11, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 11, 2024

OCUL$6.61-3.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)


· · Year Ended December 31,

· 2023 · 2022 · 2021
Cash flows from operating activities: · · ·
Net loss	$(80,736)	$(71,038)	$(6,553)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense	17,825	16,964	14,977
Non-cash interest expense	6,106	4,853	4,628
Change in fair value of derivative liabilities	5,188	(13,841)	(78,121)
Depreciation and amortization expense	2,983	2,109	2,421
Gains and losses on extinguishment of debt, net	(14,190)	—	—
Gain (loss) on disposal of property and equipment	1	1	(1)
Changes in operating assets and liabilities:
Accounts receivable	(4,854)	(190)	(8,883)
Prepaid expenses and other current assets	(3,766)	723	(101)
Inventory	(331)	(724)	(49)
Accounts payable	583	(621)	1,796
Operating lease assets	1,570	(3,175)	977
Accrued expenses	773	1,644	3,717
Deferred revenue	427	963	1,000
Operating lease liabilities	(1,813)	2,729	(1,358)
Net cash used in operating activities	(70,234)	(59,603)	(65,550)
Cash flows from investing activities:
Purchases of property and equipment	(6,087)	(3,715)	(1,194)
Net cash used in investing activities	(6,087)	(3,715)	(1,194)
Cash flows from financing activities:
Proceeds from issuance of short-term bridge loan	2,000	—	—
Proceeds from issuance of Barings notes payable	82,474	—	—
Proceeds from issuance of notes payable, net	—	—	3,722
Proceeds from exercise of stock options	551	514	2,586
Proceeds from issuance of common stock pursuant to employee stock purchase plan	851	940	985
Payments of debt financing costs	(5,184)	—	—
Proceeds from issuance of common stock upon public offering, net of issuance costs	117,261	—	—
Issuance costs from the issuance of common stock upon public offering in prior period	—	—	(275)
Repayment of MidCap notes payable	(26,125)	—	—
Repayment of notes payable	—	—	(4,167)
Repayment of short-term bridge loan	(2,000)	—	—
Net cash provided by financing activities	169,828	1,454	2,851
Net increase (decrease) in cash, cash equivalents and restricted cash	93,507	(61,864)	(63,893)
Cash, cash equivalents and restricted cash at beginning of period	104,064	165,928	229,821
Cash, cash equivalents and restricted cash at end of period	$197,571	$104,064	$165,928
Supplemental disclosure of cash flow information:
Cash paid for interest	$5,464	$2,147	$1,932
Supplemental disclosure of non-cash investing and financing activities:
Additions to property and equipment included in accounts payable and accrued expenses	$16	$1,384	$181

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.